News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
552,863 Results
Type
Article (44907)
Company Profile (107)
Press Release (507849)
Section
Business (159195)
Career Advice (1518)
Deals (29696)
Drug Delivery (88)
Drug Development (70928)
Employer Resources (116)
FDA (14919)
Job Trends (12500)
News (282771)
Policy (31165)
Tag
Academia (2474)
Africa (721)
Alliances (48258)
Alzheimer's disease (1079)
Approvals (14849)
Arizona (112)
Artificial intelligence (68)
Asia (34860)
Australia (5971)
Bankruptcy (278)
Best Places to Work (9759)
Biotechnology (73)
Breast cancer (59)
C2C Services and Suppliers (67575)
California (1535)
Canada (792)
Cancer (511)
Career advice (1281)
Cell therapy (125)
China (143)
Clinical research (55624)
Collaboration (150)
Colorado (66)
Compensation (72)
Connecticut (69)
COVID-19 (2572)
Cystic fibrosis (53)
Data (329)
Diabetes (81)
Diagnostics (4836)
Drug pricing (76)
Earnings (54628)
Employer resources (105)
Europe (77223)
Events (71966)
Executive appointments (132)
FDA (15156)
Florida (233)
Funding (135)
Gene therapy (91)
GLP-1 (547)
Government (4470)
Healthcare (16736)
Hotbed/Location (363973)
Illinois (226)
Indiana (135)
Infectious disease (2607)
Inflammatory bowel disease (87)
Interviews (250)
IPO (12760)
Job creations (2896)
Job search strategy (1126)
Kansas (84)
Layoffs (306)
Legal (7838)
Liver cancer (55)
Lung cancer (111)
Manufacturing (92)
Maryland (386)
Massachusetts (1147)
Medical device (13224)
Medtech (13228)
Mergers & acquisitions (16862)
Metabolic disorders (276)
Michigan (85)
Minnesota (163)
Neuroscience (1227)
New Jersey (488)
New York (509)
NextGen Class of 2024 (5667)
Non-profit (4002)
North Carolina (468)
Northern California (703)
Obesity (175)
Ohio (92)
Opinion (177)
Patents (73)
Pennsylvania (473)
People (44051)
Phase I (16882)
Phase II (24395)
Phase III (18957)
Pipeline (99)
Policy (59)
Postmarket research (2298)
Preclinical (6822)
Radiopharmaceuticals (228)
Rare diseases (112)
Real estate (4314)
Regulatory (19849)
Research institute (2238)
Resumes & cover letters (218)
South America (989)
Southern California (623)
Startups (3005)
Texas (210)
United States (7005)
Vaccines (537)
Washington State (169)
Weight loss (159)
Date
Today (102)
Last 7 days (437)
Last 30 days (2129)
Last 365 days (31280)
2024 (22395)
2023 (33819)
2022 (44123)
2021 (47703)
2020 (46651)
2019 (40362)
2018 (30885)
2017 (28017)
2016 (26987)
2015 (31071)
2014 (24065)
2013 (20092)
2012 (21541)
2011 (22164)
2010 (20464)
552,863 Results for "auris medical ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Press Releases
Hardy Diagnostics Releases Enrichment Broth for Candida auris Detection
July 16, 2024
·
4 min read
Drug Development
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris.
May 23, 2024
·
4 min read
Press Releases
Viromed Medical AG Plans to Acquire All Shares of ActivCell Group AG by Way of a Capital Increase Against Contribution in Kind with Exclusion of Subscription Rights
September 17, 2024
·
1 min read
Press Releases
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff
August 27, 2024
·
5 min read
Drug Development
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
60 Degrees Pharmaceuticals, Inc. announced it will, through its majority-owned subsidiary 60P Australia Pty Ltd, sponsor a series of animal studies to investigate whether single dose parenteral administration of tafenoquine exhibits efficacy against Candida spp, including Candida auris.
February 20, 2024
·
9 min read
Business
Alamar Biosciences and Biomarkers of Aging Consortium Join Forces to Revolutionize Longevity Research
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease in collaboration with the Biomarkers of Aging Consortium announced the launch of the next phase of the Biomarkers of Aging Challenge Series.
June 27, 2024
·
3 min read
GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Research Report
Sirona Biochem Corp. is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare’s newly published research report, “Novel Treatments for Age-Related Skin Problems.” The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market.
June 18, 2024
·
3 min read
Business
Araris Biotech AG Appoints Dr. Ulf Grawunder to Scientific Advisory Board
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate - technology, announced the appointment of Ulf Grawunder, Ph.D. to its scientific advisory board.
June 13, 2024
·
3 min read
FDA
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
GSK plc announced that the US Food and Drug Administration has approved AREXVY Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease in adults 50 through 59 years of age who are at increased risk.
June 7, 2024
·
8 min read
1 of 55,287
Next